Suppr超能文献

[白塞病的眼部受累:α-2a干扰素治疗后视觉发育的首个5年结果]

[Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a].

作者信息

Deuter C M E, Kötter I, Günaydin I, Zierhut M, Stübiger N

机构信息

Abteilung I-Erkrankungen des vorderen und hinteren Augenabschnittes, Universitäts-Augenklinik, Tuebingen.

出版信息

Ophthalmologe. 2004 Feb;101(2):129-34. doi: 10.1007/s00347-003-0927-7.

Abstract

BACKGROUND

Behçet's disease (BD) is a systemic vasculitis of unknown origin. Up to now ocular involvement has a poor visual prognosis irrespective of immunosuppressive treatment. Now recent open studies have shown that interferon alfa-2a (IFN alfa-2a) is very effective in the treatment of ocular BD. The purpose of this study was to evaluate the long-term development of visual acuity (VA) in patients with severe ocular BD who were treated with IFN alfa-2a.

METHODS

We included 15 eyes of 9 patients with an active panuveitis and/or retinal vasculitis due to BD refractory to immunosuppressive treatment. VA before initiation of IFN-therapy was compared to VA at the end of the follow-up time.

RESULTS

Mean follow-up time was 68.8+/-10.6 months. Mean duration of IFN-treatment was 40.6+/-17.0 months. With the exception of one patient IFN alfa-2a could be discontinued in complete remission of ocular symptoms. During the follow-up time 10 eyes showed an increase of VA of two lines or more. In 5 eyes VA remained stable. There was no decrease of VA in any eye. If a macular edema was present, a quick response to IFN alfa-2a was seen. No eye developed a pale optic disk during follow-up.

CONCLUSION

Compared to conventional immunosuppressants, interferon alfa-2a seems to be much more effective to prevent a loss or decrease of VA over a long period of time in patients with severe ocular BD.

摘要

背景

白塞病(BD)是一种病因不明的系统性血管炎。迄今为止,无论采用免疫抑制治疗与否,眼部受累的视力预后都很差。近期的开放性研究表明,干扰素α-2a(IFNα-2a)在治疗眼部白塞病方面非常有效。本研究的目的是评估接受IFNα-2a治疗的重症眼部白塞病患者视力(VA)的长期发展情况。

方法

我们纳入了9例因免疫抑制治疗无效而患有活动性全葡萄膜炎和/或视网膜血管炎的白塞病患者的15只眼睛。将IFN治疗开始前的视力与随访结束时的视力进行比较。

结果

平均随访时间为68.8±10.6个月。IFN治疗的平均持续时间为40.6±17.0个月。除1例患者外,IFNα-2a可在眼部症状完全缓解后停药。在随访期间,10只眼睛的视力提高了两行或更多。5只眼睛的视力保持稳定。没有一只眼睛的视力下降。如果存在黄斑水肿,可观察到对IFNα-2a的快速反应。随访期间没有一只眼睛出现视盘苍白。

结论

与传统免疫抑制剂相比,干扰素α-2a似乎在预防重症眼部白塞病患者长期视力丧失或下降方面更有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验